http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2017358367-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_643dd0c0767afa02bc04c1b58e953505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4418 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4412 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate | 2017-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7924e80be97a19c61c411c6835878ad1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b9ac36149e79035d6d2ce23fc2186a3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e462f89d811fe9d506ff93ea7de2cc6 |
| publicationDate | 2019-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2017358367-A1 |
| titleOfInvention | Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD/NASH) |
| abstract | The present invention relates to the use of a pharmaceutical composition in the form of extended-release tablets containing pirfenidone for the treatment of NAFLD / NASH and advanced liver fibrosis, by reducing serum cholesterol and triglycerides, as well as reducing the content of hepatic fat accumulation, both in the form of macrosteatosis and microsteatosis. The invention also relates to the use of the composition as an agonist for PPARgamma (peroxisome proliferation receptor activated gamma), PPARalpha (peroxisome proliferation receptor activated alpha), LXR and CPT1, key molecules in the metabolism of fatty degradation and inflammation of the liver. In addition, another use is the induction of decreased expression of the NFkB master gene, transcriptional inducer of hepatic inflammatory process factor. All of these events result in the reversal of NAFLD / NASH and advanced liver fibrosis. |
| priorityDate | 2016-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 437.